What Supported the Alprazolam Association in an Anorgasmia Case?
A repeated symptom pattern can support a proposed adverse drug reaction, although the evidence remains specific to the person observed. A 2018 alprazolam case report examined sexual symptoms in a patient taking several psychotropic medications.
The documented pattern
Other psychotropic doses had remained stable for more than six months while extended-release alprazolam was increased for anxiety. The patient reported new anorgasmia within a week of reaching the higher daily amount. Over ten weeks, self-directed reductions on weekends repeatedly coincided with improved orgasmic function.
What the authors inferred
The authors assessed the reaction as probable using the Naranjo scale. They considered the chronology, repeated symptom changes, stable co-medications, and competing medical and psychiatric explanations. A subsequent change in the patient’s dosing schedule also led them to suggest a concentration-related component.
Which questions remained open?
The report’s observed symptom and dosing history supported an association. The proposed relationship to concentration remained an inference because the described pattern itself supplied no measured alprazolam concentration curve. Concurrent drugs could also contribute pharmacodynamically even while their doses remained stable. For an attorney reviewing a claimed adverse effect, separating patient-reported changes, corroborated treatment history, a structured causality rating, and a proposed mechanism makes the opinion easier to evaluate. The case offers no incidence estimate for other patients. The self-directed medication changes were part of the reported history and should be interpreted in that observational context.
Source
Read the full scientific paper. DOI 10.1192/bjo.2018.35.
